Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Follows Novartis; Offers To Up Stake In Indian Arm To 75 Percent

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - After Novartis and Mylan, it's now Pfizer's turn to increase its equity holding in its Indian operations. In an announcement to the Bombay Stock Exchange, Pfizer said it has decided to acquire an additional stake of 33.77 percent in Pfizer India through an open offer from public shareholders at a price of 675 rupees per share ($13.23)
Advertisement

Related Content

GSK Pumps In $1 Billion To Raise Equity In Indian Pharma Subsidiary
Listing Of MNC Divisions In India Has Been Rough Ride With Stray Sparks Of Hope
Are Emerging Markets Part Of Big Pharma's Core Business?
Listing Of MNC Arms In India Has Been Rough Ride With Stray Sparks Of Hope
Sanofi-Aventis To Consolidate Further In India As Longtime Shareholder United Breweries Exits
Pfizer’s Champix Faces Patent Hurdle In India As Dr Reddy’s Raise Questions
Novartis Wants Tighter Grip Over Its Indian Ops; Announces Open Offer To Up Stake To 90%
Pfizer Pushes Champix In India Through Private Hospitals And Clinics As Smoking Epidemic Hits India
As Pfizer-Wyeth Combine Eye Vaccines Business, Novartis, GSK, Sanofi-Aventis And Indian Companies Brace For The Challenge
As Pfizer-Wyeth Combine Eye Vaccines Business, Novartis, GSK, Sanofi-Aventis And Indian Companies Brace For The Challenge
Advertisement
UsernamePublicRestriction

Register

SC071317

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel